Citation Impact
Citing Papers
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
The epidemiology of carcinoid tumours in England and Scotland
1994
Epigenetics: A Landscape Takes Shape
2007 Standout
Chemoradiotherapy of Locally Advanced Esophageal Cancer
1999 Standout
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study
1988
Cisplatin nephrotoxicity
1989
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Epigenetic therapy of cancer: past, present and future
2006
Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics
2010 StandoutNobel
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
2007 Standout
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Treatment of neuroendocrine tumors
1994
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus
1992 Standout
Chemotherapy for pancreatic carcinoma
1996
Cisplatin Nephrotoxicity: A Review
2007 Standout
Epigenetics in Cancer
2008 Standout
Epigenetics in cancer
2009 Standout
A population model for the leukopenic effect of etoposide*
1995
Neuroendocrine gastrointestinal tumours
1996
Toxicity profile of dexrazoxane (zinecardR, icrf-187, adr-529, nsc-169780), a modulator of doxorubicin cardiotoxicity
1991
Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody
1999
A 5‐decade analysis of 13,715 carcinoid tumors
2003 Standout
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
2003 Standout
Carcinoid tumors of Meckel's diverticula
1992
Rectal carcinoids
1992
Cisplatin: The first metal based anticancer drug
2019 Standout
An analysis of 8305 cases of carcinoid tumors
2000 Standout
Oxaliplatin clinical activity: a review
2000
Natural compounds for cancer treatment and prevention
2009 Standout
CARClNOlD SYNDROME SECONDARY TO A PRIMARY TUMOUR IN A MECKEL'S DIVERTICULUM
1993
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Automated Covariate Model Building Within NONMEM
1998 Standout
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Environmental epigenomics and disease susceptibility
2007 Standout
Cisplatin nephrotoxicity
2003 Standout
Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years
2001
Carcinoid Tumors of the Appendix
1993
Perspectives in cancer chemotherapy
2001
Platinum nephrotoxicity
1978
Magnesium in Man: Implications for Health and Disease
2014 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin
1979
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
2004
Hearing loss in children receiving cisplatin chemotherapy
1983
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells
2006 StandoutNobel
Renal and metabolic toxicities of cancer chemotherapy.
1982
Method for Dissection of Mesenteric Metastases in Mid‐gut Carcinoid Tumors
2000
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
2007 Standout
Carcinoid Tumors of the Gut
1997
Epigenetic regulation of redox state mediates persistent cardiorespiratory abnormalities after long‐term intermittent hypoxia
2016 StandoutNobel
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin
1982
VP-16-213 (etoposide): The mandrake root from Issyk-Kul
1982
Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites
2003
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
2001
Cis-diamminedichloroplatinum (II)
1977
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
2001
Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
2004 Standout
Cisplatin
1984 Standout
Works of Schutt Aj being referenced
Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
1976
Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
1975
Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel.
1974
Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin (NSC-125066).
1974
Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis.
1985
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
1972
Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination.
1976
Phase II study of pyrazofurin in advanced colorectal carcinoma.
1977
Phase II study of PALA in advanced large bowel carcinoma.
1981
Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
1980